

## CURRICULUM VITAE



### PERSONAL INFORMATIONS

Name	<b>LUCA DOMINICI</b>
Adress	<b>VIA GIOVANNI DOTTO, 12, 90129, PALERMO, ITALY</b>
Telephone number	<b>+39 3298911152</b>
E-mail	LUCA.DOMINICI@HUMANITAS.IT
Codice Fiscale	DMNLCU89A19G273V
Nationality	Italian
Date of birth	19/01/1989
Gender	M
Professional title	DOCTOR RECORDED WITH NR.15482 AT THE PALERMO'S PROVINCIAL PROFESSIONAL REGISTER OF DOCTORS AND SURGEONS.

### PROFESSIONAL WORK

#### EXPERIENCE

- Date (from-to) November 2016 – November 2020
- Name and address of the employer AOUC Careggi, Department of Radiation Oncology, Florence.
  - Sector Radiotherapy
  - Employment Resident in Radiation Oncology

- Main tasks First Medical visits, Control visits, Revaluation visits, Chemoterapy drugs administrations, Radiotherapy planning programs. Sub-investigator in clinical trials with particular interest to Breast Cancer, Prostate Cancer, Lung Cancer.
  
- Date (from-to) November 2019 – February 2020
- Name and address of the employed Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Hospital, Rozzano (Milan), Italy Radiotherapy
  - Sector Resident in Radiation Oncology – Research Fellow
  - Employment First Medical visits, Control visits, Revaluation visits, Radiotherapy planning programs (SBRT - SRS). Sub-investigator in clinical trials with particular interest to Breast Cancer, Lung Cancer.
  - Main task
  
- Date (from-to) May 2020 – October 2020
- Name and address of the employed Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Hospital, Rozzano (Milan), Italy Radiotherapy
  - Sector Resident in Radiation Oncology – Research Fellow
  - Employment First Medical visits, Control visits, Revaluation visits, Radiotherapy planning programs (SBRT - SRS). Sub-investigator in clinical trials with particular interest to Breast Cancer, Lung Cancer.
  - Main task
  
- Date (from-to) Novembre 2020 – Present
- Name and address of the employed Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Hospital, Rozzano (Milan), Italy
  - Sector Radiotherapy
  - Employment Assistant Radiation oncologist
  - Main task Main interest in lung cancer and other thoracic tumors, breast cancer and esophageal cancer, stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) for oligometastases, combination between radiotherapy and immunotherapy.

## EDUCATION AND TRAINING

- Date 02/2016
- Name and type of training institution Palermo University
  - Qualification obtained Enabled medical profession
  
- Date October 2015
- Name and type of training institution Palermo University, degree course in Medicine and Surgery.
  - Qualification obtained Degree in Medicine and Surgery with vote 110/110
  
- Date July 2007
- Qualification obtained High school classical studies degree

**SKILLS AND PERSONAL  
COMPETENCES**

NATIVE LANGUAGE    **ITALIAN**

OTHER LANGUAGE

**ENGLISH**

- Reading ability    GOOD
- Writing skills    GOOD
- Verbal skills    GOOD

CAPACITY IN TECHNICAL SKILLS

**Informatical skills**

**Operating system:** Windows XP, Vista, 7, 10

**Microsoft Office:** Good knowledge of Word, Excel e Powerpoint.

## RELATIONAL SKILLS

I am tidy and precise. I am reliable and I have organizational skills that allow me to be punctual in terms of deadlines. I am suitable for various situations, I like to receive input that leads me to do analysis to extend my knowledge. I am very capable of doing teamwork.

## PUBLICATIONS

1) Analysis of skin dose distribution for the prediction of severe radiation dermatitis in head and neck squamous cell carcinoma patients treated with concurrent chemoradiotherapy. Authors: Bonomo P, Talamonti C, Desideri I, Marrazzo L, Pezzulla D, Rampini A, Bertocci S, De Majo R, Gasperi C, Curion AS, Lastrucci L, Dominici L, Pallotta S, Livi L, Caini S .Rivista scientifica: Head Neck 2019 Nov 4. doi: 10.1002/hed.25997.

2) Stereotactic body radiation therapy (SBRT) on renal cell carcinoma, an overview of technical aspects, biological rationale and current literature. Authors: Francolini G, Detti B, Ingrosso G, Desideri I, Becherini C, Carta G, Pezzulla D, Caramia G, Dominici L, Maragna V, Teriaca MA, Bottero M, Livi L Rivista scientifica: Crit Rev Oncol Hematol. 2018 Nov;131:24-29. doi:10.1016/j.critrevonc.2018.08.010.

3) hERG1 channel expression associates with molecular subtypes and prognosis in breast cancer. Authors: Jessica Iorio, Icro Meattini, Simonetta Bianchi, Marco Bernini, Virginia Maragna, Luca Dominici, Donato Casella, Vania Vezzosi, Lorenzo Orzalesi, Jacopo Nori, Lorenzo Livi, Annarosa Arcangeli and Elena Lastraioli. Rivista scientifica: Cancer Cell Int. 2018 Jul 5;18:93. doi: 10.1186/s12935-018-0592-1. eCollection 2018.

4) Soft tissue sarcomas: new opportunity of treatment with PARP inhibitors? Authors: Monica Mangoni, Mariangela Sottili, Giulia Salvatore, Domenico Campanacci, Guido Scoccianti, Giovanni Beltrami, Camilla Delli Paoli, Luca Dominici, Virginia Maragna, Emanuela Olmetto, Icro Meattini, Isacco Desideri, Pierluigi Bonomo, Daniela Greto, Lorenzo Livi Rivista scientifica: Radiol Med. 2019 Apr;124(4):282-289. doi: 10.1007/s11547-018-0877-4. Epub 2018 Mar 26

5) Enhancement of Soft Tissue Sarcoma Cell Radiosensitivity by Poly(ADP-ribose) Polymerase1 Inhibitors. Authors: Mangoni M, Sottili M, Salvatore G, Meattini I, Desideri I, Greto D, Loi M, Becherini C, Garlatti P, Delli Paoli C, Dominici L, Gerini C, Scoccianti S, Bonomo P, Silvano A, Beltrami G, Campanacci D, Livi L .Rivista scientifica: Radiat Res. 2018 Nov;190(5):464-472. doi: 10.1667/RR15035.1.

6) Management of liposarcoma: A single institutional analysis. Authors: Daniela Greto, Carlotta Becherini, Calogero Saieva, Giulio Francolini, Domenico Andrea Campanacci, Giovanni Beltrami, Guido Scoccianti, Icro Meattini, Mauro Loi, Pierluigi Bonomo, Isacco Desideri, Camilla Delli Paoli, Luca Dominici, and Lorenzo Livi. Journal of Clinical Oncology 2017 35:15\_suppl, e22531-e22531

7) Poster ESTRO 38: Transition from anatomical to geometric expansion modality for high-risk CTV in oropharyngeal cancer. Bonomo P, Desideri I, Becherini C, Visani L, Garlatti P, Dominici L, Livi L

8) Poster ESTRO 38: Is skin dose distribution a predictive factor for development of severe of radiation dermatitis?. Bonomo P, Talamonti C, Desideri I, Marrazzo L, Pezzulla D, Dominici L, Rampini A, Bertocci, De Majo, Gasperi, Curion, Lastrucci, Pallotta S, Livi L, Caini

9) Oral presentation AIRO 2019: DETECTION RATE, PATTERN OF RELAPSE AND INFLUENCE ON THERAPEUTIC DECISION OF PSMA PET/CT IN PATIENTS AFFECTED BY BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY, A RETROSPECTIVE

CASE-SERIES . L. Dominici, G. Ingrosso, A. Bruni, S. Borghesi, M. Bottero, A. Lancia, A.R. Filippi, R. Santoni, C. Aristei, E. Mazzeo, L. Frassinelli, G. Francolini, B. Detti, L. Livi

10) Poster AIRO 2019: PATTERN OF LOCOREGIONAL FAILURE IN BREAST CANCER PATIENTS TREATED WITH ADJUVANT RADIOTHERAPY AFTER MODIFIED RADICAL MASTECTOMY AND BREAST RECONSTRUCTION: A SINGLE INSTITUTION EXPERIENCE. C. Ciabatti, M. Lo Russo, S. Lucidi, V. Lorenzetti, P. Garlatti, M. Perna, L. Dominici, C. Becherini, I. Desideri, V. Scotti, I. Meattini, L. Livi AOU Careggi, Università degli Studi di Firenze, Italy

11) Poster AIRO 2019: ANTI-EMETIC EFFICACY OF FOSAPREPITANT REGIMEN IN LOCALLY ADVANCED HEAD AND NECK CANCER UNDERGOING CISPLATIN-BASED CHEMO-RADIATION: PILOT COHORT STUDY. B. Guerrieri, V. Maragna, L. Visani, C. Becherini, G. Stocchi, M.A. Teriaca, G. Caramia, L. Dominici, V. Scotti, I. Desideri, P. Bonomo, L. Livi AOU Careggi, Università degli Studi Di Firenze, Italy

12) Stereotactic Radiotherapy for Ultra-Central Lung Oligometastases in Non-Small-Cell Lung Cancer. Loi M, Franceschini D, Dominici L, Franzese C, Chiola I, Comito T, Marzo M, Reggiori G, Mancosu P, Tomatis S, Nuyttens J, Scorsetti M. . *Cancers (Basel)*. 2020 Apr 5;12(4). pii: E885. doi: 10.3390/cancers12040885. PubMed PMID: 32260568.

13) Cyclin-Dependent Kinase 4/6 Inhibitors Combined With Radiotherapy for Patients With Metastatic Breast Cancer. *Clin Breast Cancer*. Ratoso I, Orazem M, Scoccimarro E, Steinacher M, Dominici L, Aquilano M, Cerbai C, Desideri I, Ribnikar D, Marinko T, Livi L, Meattini I. 2020 May 26:S1526-8209(20)30115-4. doi: 10.1016/j.clbc.2020.05.013. Epub ahead of print. PMID: 32622736.

14) Loi M, Comito T, Franzese C, Dominici L, Lo Faro L, Clerici E, Franceschini D, Mancosu P, Reggiori G, Gallo P, Badalamenti M, Scorsetti M. Stereotactic body radiotherapy in hepatocellular carcinoma: patient selection and predictors of outcome and toxicity. *J Cancer Res Clin Oncol*. 2021 Mar;147(3):927-936. doi: 10.1007/s00432-020-03389-2. Epub 2020 Sep 18. PMID: 32945972.

15) Ghirardelli P, Franceschini D, D'Aveni A, Dominici L, Ravasio A, Marzo M, Villa E, Di Noia V, Scorsetti M, Vavassori V, Ceresoli GL. Salvage radiotherapy for oligo-progressive malignant pleural mesothelioma. *Lung Cancer*. 2021 Feb;152:1-6. doi: 10.1016/j.lungcan.2020.11.022. Epub 2020 Nov 26. PMID: 33310300.

16) Loi M, Franceschini D, Dominici L, Chiola I, Franzese C, D'Agostino GR, Navarra P, Marzo M, Paganini L, Comito T, Mancosu P, Tomatis S, Cozzi L, Alifano M, Scorsetti M. Dose coverage impacts local control in ultra-central lung oligometastases treated with stereotactic radiotherapy. *Strahlenther Onkol*. 2021 May;197(5):396-404. doi: 10.1007/s00066-020-01687-9. Epub 2020 Sep 24. PMID: 32970163.

17) Loi M, Comito T, Franzese C, Desideri I, Dominici L, Lo Faro L, Clerici E, Franceschini D, Baldaccini D, Badalamenti M, Reggiori G, Lobefalo F, Scorsetti M. Charlson comorbidity index and G8 in older old adult(≥80 years) hepatocellular carcinoma patients treated with stereotactic body radiotherapy. *J Geriatr Oncol*. 2021 Jan 15:S1879-4068(21)00001-1. doi: 10.1016/j.jgo.2021.01.001. Epub ahead of print. PMID: 33461945.

18) Massaro M, Franceschini D, Spoto R, Dominici L, Franzese C, Baldaccini D, Marini B, di Cristina L, Marzo MA, Lo Faro L, Paganini L, Reggiori G, Galdieri C, Testori A, Scorsetti M. Locally Advanced Non-Small Cell Lung Cancer: Clinical Outcome, Toxicity and Predictive Factors in Patients Treated with Hypofractionated Sequential or Exclusive Radiotherapy. *Curr Oncol*. 2022 Jul 12;29(7):4893-4901. doi: 10.3390/curroncol29070388. PMID: 35877248; PMCID: PMC9325151.

19) Franceschini D, Teriaca MA, Dominici L, Franzese C, Scorsetti M. Knowing When to Use Stereotactic Ablative Radiation Therapy in Oligometastatic Cancer. *Cancer Manag Res*. 2021 Sep 7;13:7009-7031. doi: 10.2147/CMAR.S294116. PMID: 34522143; PMCID: PMC8434826.

**Autorizzo il trattamento dei miei dati personali a i sensi del Dlgs 196 del 30 giugno 2003**

Rozzano, 17 – Aug - 2022

Luca Dominici